Sorrento Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 460 584 529 683
Cost of Revenue 4 - - -
Gross Profit 456 584 529 683
Operating Expenses
Research and Development 9,017 3,830 2,570 1,392
Sales, General and Admin. 6,317 1,606 1,201 1,102
Non-Recurring Items 5,986 - - -
Other 804 - - -
Operating Income (21,668) (4,853) (3,242) (1,812)
Income From Continuing Operations
Add'l Income/Expense Items 10 7 6 4
Earnings Before Interest and Tax (21,658) (4,845) (3,236) (1,808)
Interest Expense 253 - - -
Earnings Before Tax (21,911) (4,845) (3,236) (1,808)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (21,911) (4,845) (3,236) (1,808)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (21,911) (4,845) (3,236) (1,808)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (21,911) (4,845) (3,236) (1,808)